Johnson & Johnson stock at EUR 227.53, up 24.0 percent year to date

Published on 10/08/2026 at 19:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 52-week span is USD 184.66 to USD 281.07. Johnson & Johnson stock costs EUR 227.53 on October 8, 2026 versus EUR 231.83.

Key points in brief

Johnson & Johnson stock was at EUR 227.53 at Lang & Schwarz on October 8, 2026 at 7:47 p.m. CEST, down 1.85 percent from EUR 231.83.
The stock's USD 184.66 to USD 281.07 52-week range places the euro quote below the converted upper end.
Johnson & Johnson had a USD 615.5 billion market capitalization and a P/E ratio of 29.57 as of October 8, 2026.
Pfizer fell 0.84 percent and AbbVie fell 0.53 percent on October 8, 2026, compared with Johnson & Johnson's 1.85 percent decline.

Extreme macro photograph of a single white pharmaceutical tablet on a pale grey surface, a fine score line running diagonally across its center in sharp focus, micro-granular chalky texture visible across the pill surface, soft diffuse highlights along th — Johnson Pharmapille im Makro, US4781601046 zeigt Bruchrille und feine Tablet Textur im Detail, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 227.53 at Lang & Schwarz on October 8, 2026 at 7:47 p.m. CEST, down 1.85 percent versus the prior close of EUR 231.83. The move gives the stock a clear daily position below the previous session's level, while the broader valuation picture remains tied to its healthcare scale.

Bid and ask mark the session

The bid stood at EUR 227.50 and the ask at EUR 227.55 at the same Lang & Schwarz timestamp. The narrow EUR 0.05 spread places the quoted market immediately around the latest traded level and gives investors a precise intraday reference for the after-hours phase.

Johnson & Johnson's primary listing is the New York Stock Exchange under ticker JNJ, and the security carries ISIN US4781601046, according to TradingView. The company operates in healthcare, with pharmaceuticals and medical technology as its main business areas.

Year to date remains positive

The 52-week range runs from USD 184.66 to USD 281.07. The Lang & Schwarz quote is therefore below the upper end of the home-market range, while the stock remains up 24.00 percent year to date according to Investing.com as of its October 6, 2026 report. That combination shows why a single-session decline does not describe the full 2026 performance.

Valuation and market size

Johnson & Johnson had a market capitalization of USD 615.5 billion, a P/E ratio of 29.57 and a dividend yield of 2.00 percent as of October 8, 2026. The valuation figures place the company among the largest healthcare stocks, with the dividend yield adding an income component to the market profile.

Comparison with peers

Johnson & Johnson: minus 1.85 percent, P/E 29.57, market capitalization USD 615.5 billion.

Pfizer (NYSE, USD): minus 0.84 percent, P/E 36.66, market capitalization USD 158.2 billion.

AbbVie (NYSE, USD): minus 0.53 percent, P/E 76.04, market capitalization USD 476.9 billion.

Price remains the key reference

The Lang & Schwarz quote leaves Johnson & Johnson below its prior close of EUR 231.83, while the USD 615.5 billion market capitalization and 24.00 percent year-to-date gain provide the wider market context. The stock's next trading sessions will be measured against the EUR 227.53 after-hours level.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.